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Accepted 11 November 2014It is time to look back to the last 15 to 20 years of stem cell
transplantation. One of the most obvious changes has been
the replacement of bone marrow by peripheral blood leu-
kocytes enriched for stem cells. It is more convenient to
collect stem cells from the peripheral blood after a 4-day
treatment with hematopoietic growth factor, mostly gran-
ulocyte colonyestimulating factor. It spares anesthesia and
multiple wounds of the pelvic crest necessary for bone
marrow aspiration. In the short term, serious adverse events
are rare and long-term effects of blood stem cells donation
have not been deﬁned yet [1].
Is there an advantage for the patient? Most randomized
studies show faster recovery of neutrophils and some show
even faster recovery of platelets [2-8]. Therefore, it is not
surprising that peripheral blood stem cells are the preferred
graft for frail patients, sick patients with advanced disease,
and patients conditionedwith a regimen of reduced intensity
[8]. There were no differences in survival in patients given
bone marrow compared with those who received peripheral
blood stem cells, except for patients who underwent trans-
plantation inﬁrst remission of chronicmyelogenous leukemia
(CML) [9]. In other forms of leukemia and in advanced stages
of CML, there was no signiﬁcant survival advantage of bone
marrowover blood stemcells [10]. There aremanydifferences
between the group given blood stem cells and that given
marrow (Table 1 fromreference [10]). In thegroupgivenblood
stem cells, there were more elderly patients, more patients
with a poorer performance, and more patients with condi-
tioning of reduced intensity, including busulfan and ﬂudar-
abine or busulfan and cyclophosphamide. Patients with blood
stem cell transplantation were more frequent in recent yearsDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.09.006.
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http://dx.doi.org/10.1016/j.bbmt.2014.11.011of 2005 to 2009, comparedwithmarrow transplant recipients
in 2000 to 2004; they received more cells and more often
received tacrolimus insteadof cyclosporineA for graft-versus-
host disease (GVHD) prophylaxis. Therefore, the blood stem
cell group may have had several favorable factors that cannot
be controlled in a multicenter retrospective analysis. In spite
of these favorable factors, nonrelapse mortality is not lower
than in the bonemarrowgroup (Table 2 of reference [10]). It is
even higher in patients with CML in ﬁrst chronic phase and
preleukemic myelodysplasia (refractory anemia with excess
blasts (RAEB)-1 andrefractoryanemiawithexcessblasts-2). In
the latter, nonrelapsemortality is counterbalanced by a lower
relapse rate, so that survival is the same as in the marrow
group. In patients with CML in ﬁrst chronic phase, the relapse
rate is low inbothgroups, so the lowernonrelapsemortality of
the marrow group results in a better survival.
Better survival of patients who underwent transplantation
with blood stem cells was reported by Bensinger et al. [8], but
this effect was most pronounced in patients with advanced
disease. The survival curves of Eapen et al. [10] in the second
and third year after transplantation for acute leukemia also
show better survival of patients given blood stem cells, but the
curves come together after 5 years, conﬁrming the early
advantage of blood stem cells in this disease (Figure 1 of
reference [10]). The samecanbeseen inRAEBpatients (Figure2
in reference [10]). In patients with CML, those given bone
marrow fare better than those given blood stem cells (Figure 3
of reference [10]), but this difference is only signiﬁcant in pa-
tients who underwent transplantation in ﬁrst chronic phase.
Certainly, it is highly speculative to draw any conclusions
from a retrospective multicenter study with so many un-
controllable factors. Nevertheless, a pattern can be recog-
nized: bone marrow may be the preferred stem cell source
for patients with less progressive forms of leukemia and
myelodysplasia and certainly for patients with nonmalignant
diseases [11]. Obviously, blood stem cell transplantatoins
produce more GVHD that is harmful in nonmalignant dis-
eases and not helpful in chronic phase CML. Chronic GVHD is
helpful in the control of acute leukemia and it may improve
survival, as long as it is limited.
The role of T cells has been most convincingly shown in
CML; patients given T celledepleted grafts had a signiﬁcantly
increased risk of relapse [12], and transfusion of lymphocytes
from the marrow donor could induce lasting remissions [13].
K.R. Schultz / Biol Blood Marrow Transplant 21 (2015) 1e32Better survival and leukemia control may have been ex-
pected from blood stem cell transplantation, but more severe
GVHD was a matter of concern because the content of T cells
is about 10-fold higher than in aspirated marrow [14]. The
higher content of T cells and the higher content of CD34þ
CD38- stem cells may be responsible for the faster recovery of
leukocytes and platelets [3,5,8,15-17], less frequent graft
failures [9], and better immune recovery [18]. A higher
incidence of chronic GVHD was found in large retrospective
studies [19,20], but the rate and severity of acute GVHD,
incidence of relapse, and survival were not different. How-
ever, as time goes by, chronic GVHD charges toll in reducing
survival of good-risk patients. Unlike these patients with
nonmalignant or slowly progressivemalignant disease, those
with acute leukemia and progressive disease, elderly and
frail patients, and patients conditioned with reduced in-
tensity may beneﬁt from blood stem cell transplantations
and better control of leukemia with some chronic GVHD.
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Accepted 10 November 2014The paper by Rezvani et al. [1], “The Impact of Donor Age
on Outcome after Allogeneic Hematopoietic CellTransplantation” appearing in this issue and on which this
commentary is based, demonstrates that an older donor age
does not negatively affect engraftment, graft-versus-host
disease (GVHD), relapse, or mortality after blood and
marrow transplantation. The authors evaluated the periph-
eral blood progenitor cell (PBPC) product in donors over the
age of 60 years compared with that of younger donors. Their
conclusion is surprising, as it is well established that use of
younger donors, under 20 years of age, is associated with
lower rates of acute and chronic GVHD than use of donors
older than 20 years [2]. Moreover, use of umbilical cord
blood, the youngest donor source, is associated with the
lowest rate of GVHD of any donor source. Umbilical cord
blood as a donor product is limited by its high graft failure
rate, probably because of its low numbers of memory T cells,
even when high cell numbers are infused [3]. On the other
